Evidence map›Paper›PMID 36733804›Full record

ArticleFrontiers in endocrinology2022

Obesity management: Attitudes and practice of Italian endocrinologists.

Marco Chianelli, Luca Busetto, Roberto Attanasio, Olga Eugenia Disoteo, Giorgio Borretta, Agnese Persichetti, Irene Samperi, Alessandro Scoppola, Agostino Paoletta, Franco Grimaldi and 2 more

Full text read
In one paragraph

Article in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Marco ChianelliEndocrinology Unit, Regina Apostolorum Hospital, Rome, Italy.
Luca BusettoDepartment of Medicine, University of Padova, Padova, Italy.
Roberto AttanasioScientific Committee of the Italian Association of Clinical Endocrinologists, Milan, Italy.
Olga Eugenia DisoteoSC Diabetologia, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
Giorgio BorrettaDepartment of Endocrinology, Diabetes and Metabolism, Santa Croce & Carle Hospital, Cuneo, Italy.
Agnese PersichettiService of Pharmacovigilance, IRCCS-Regina Elena National Cancer Institute, Rome, Italy.
Irene SamperiSSD of Diabetology, Azienda Sanitaria Locale, Novara, Italy.
Alessandro ScoppolaEndocrinology Unit, Santo Spirito Hospital, Rome, Italy.
Agostino PaolettaEndocrinology, ULSS 6 Euganea, Padova, Italy.
Franco GrimaldiEndocrinology, Diseases of Metabolism and Clinical Nutrition Unit, University Hospital S.M. Misericordia, Udine, Italy.
Enrico PapiniEndocrinology and Metabolism - Regina Apostolorum Hospital, Roma, Italy.
Antonio NicolucciCenter for Outcomes Research and Clinical Epidemiology - CORESEARCH, Pescara, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Obesity is a global pandemic and is cause of serious concern in all regions of the world. It is important to raise the attention of health care professionals in order to provide early treatment of patients with obesity. Obesity management, however, varies greatly amongst endocrinologists with respect to attitudes to diagnosis and treatment. Aim of this study was to identify practices and needs of Italian endocrinologists with respect to people with obesity. Methods: In this study, all members of the Italian Association of Clinical Endocrinologists (AME) were invited to participate in a web-based survey concerning the management of obesity. Results: The response rate was 24.1% (542/2248). Nutritional and obesity problems were reported as major areas of interest by 29.4% of the participants. A large proportion of patients seeking an endocrine consultation for other reasons are affected by obesity, but one in five respondents addressed the issue in 25% or less of the cases, while one in three always dealt with the problem. Obesity was managed personally/within a dedicated team by 42.6% of participants, while the remainders referred the patient to a dietician/nutritionist or a 2nd level center for obesity therapy. Metformin was used in a median of 30% of the patients (Interquartile range: 10-50) and liraglutide in 10% of the cases (IQR 0-30), while orlistat (median 0%; IQR 0-10) and naltrexone/bupropion (median 0%; IQR 0-5) were seldom prescribed. Cost of therapy was considered as the major limitation to the use of anti-obesity drugs, affecting adherence to long-term treatment. According to 41.9% of respondents, psychological support should be offered to all patients with obesity. Finally, 56% of participants believe that the availability of new drugs will increase the number of patients candidate to drug therapy. Discussion: In conclusion, it is of primary importance to raise the awareness of endocrinologists towards the problem of obesity and increase their confidence in managing this pathological condition.

Indexed as

Anti-Obesity AgentsMetforminEndocrinologistsHumansObesityOrlistatAnti-Obesity AgentsMetforminOrlistatattitudesendocrinologistsobesitysurveytreatment

Identifiers

PMID36733804
PMCPMC9888662

What OpenQuestion holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.